Peter Arlett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5573378/publications.pdf

Version: 2024-02-01

25 papers	868 citations	623734 14 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	960 citing authors

#	Article	IF	Citations
1	Realâ€World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clinical Pharmacology and Therapeutics, 2022, 111, 21-23.	4.7	87
2	Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. Clinical Pharmacology and Therapeutics, 2021, 109, 1212-1218.	4.7	97
3	Does additional monitoring status increase the reporting of adverse drug reaction<scp>s</scp>? An interrupted time series analysis of <scp>EudraVigilance</scp> data. Pharmacoepidemiology and Drug Safety, 2021, 30, 350-359.	1.9	5
4	What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?. Pharmacoepidemiology and Drug Safety, 2021, 30, 334-341.	1.9	10
5	International Collaboration in Realâ€World Evidence Generation for Direct Acting Oral Antiâ€Coagulants. Clinical Pharmacology and Therapeutics, 2021, 109, 299-301.	4.7	1
6	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International Journal of Technology Assessment in Health Care, 2021, 37, e83.	0.5	10
7	Improving the Safety of Medicines in the European Union: From Signals to Action. Clinical Pharmacology and Therapeutics, 2020, 107, 521-529.	4.7	24
8	Pharmacovigilance 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 89-91.	4.7	20
9	Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. British Journal of Clinical Pharmacology, 2020, 86, 1034-1051.	2.4	26
10	Measuring the impact of risk communications: Robust analytical approaches are key. British Journal of Clinical Pharmacology, 2020, 86, 635-636.	2.4	8
11	Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. Clinical Pharmacology and Therapeutics, 2020, 107, 957-965.	4.7	3
12	Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?. Clinical Pharmacology and Therapeutics, 2020, 107, 915-925.	4.7	11
13	A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. Pharmacoepidemiology and Drug Safety, 2019, 28, 1086-1096.	1.9	13
14	Realâ€World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. Clinical Pharmacology and Therapeutics, 2019, 106, 36-39.	4.7	180
15	Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance. Drug Safety, 2019, 42, 581-582.	3.2	1
16	EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Safety, 2018, 41, 665-675.	3.2	73
17	Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs. Drug Safety, 2018, 41, 191-202.	3.2	25
18	Registries in European postâ€marketing surveillance: a retrospective analysis of centrally approved products, 2005â€“2013. Pharmacoepidemiology and Drug Safety, 2017, 26, 1442-1450.	1.9	32

#	Article	IF	Citations
19	Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Safety, 2017, 40, 855-869.	3.2	69
20	Periodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective. Pharmaceutical Medicine, 2014, 28, 309-315.	1.9	4
21	The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac. Pharmacoepidemiology and Drug Safety, 2014, 23, 431-434.	1.9	8
22	Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nature Reviews Drug Discovery, 2014, 13, 395-397.	46.4	42
23	Increasing scientific standards, independence and transparency in postâ€authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2012, 21, 690-696.	1.9	27
24	Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiology and Drug Safety, 2012, 21, 896-899.	1.9	54
25	European Medicines Agency review of postâ€authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2011, 20, 1021-1029.	1.9	38